# Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT07007910** · PHASE1 · RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- m CRPC

## Interventions

- **DRUG:** HSK46575

## Key facts

- **NCT ID:** NCT07007910
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-18
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07007910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07007910, "Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07007910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*